The Function and Mechanism of Long Non-coding RNA-ATB in Cancers

被引:47
|
作者
Xiao, Huizhong [1 ,2 ]
Zhang, Fuyou [1 ]
Zou, Yifan [1 ,3 ]
Li, Jianfa [1 ,4 ]
Liu, Yuchen [1 ]
Huang, Weiren [1 ,2 ,3 ]
机构
[1] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Key Lab Med Reprogramming Technol, Shenzhen, Peoples R China
[2] Univ South China, Hengyang, Peoples R China
[3] Shantou Univ, Coll Med, Shantou, Peoples R China
[4] Peking Univ, Shenzhen Hosp, Inst Urol,PKU HKUST Med Ctr, Guangdong & Shenzhen Key Lab Male Reprod Med & Ge, Shenzhen, Peoples R China
基金
中国国家自然科学基金;
关键词
long non-coding RNA; ATB; human cancers; therapeutic targets; diagnostic biomarker; REGULATES CELL-PROLIFERATION; INVASION-METASTASIS CASCADE; LNCRNA-ATB; HEPATOCELLULAR-CARCINOMA; POOR-PROGNOSIS; COLORECTAL-CANCER; DOWN-REGULATION; HIGH EXPRESSION; GASTRIC-CANCER; TGF-BETA;
D O I
10.3389/fphys.2018.00321
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Long non-coding RNAs (lncRNAs) are a class of transcriptional RNA molecules with a length of greater than 200 nucleotides that function as regulatory factors in many human diseases. Studies have shown that lncRNAs are involved in multiple cellular processes, including proliferation, apoptosis, migration, and invasion. In this report, a long non-coding RNA-ATB that is overexpressed in various tumor tissues and cell lines was investigated. Recent evidence suggests that ATB is dysfunctional in a variety of cancers, including hepatocellular carcinoma, gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC), prostate cancer, renal cell carcinoma, non-small cell lung cancer (NSCLC), pancreatic cancer, osteosarcoma, and glioma. The high expression of ATB is associated with clinicopathological features of cancer patients. In addition, overexpression of lncRNA-ATB can promote tumor proliferation, migration, and invasion. LncRNA-ATB induces epithelial-mesenchymal transition (EMT) by competitively binding to miRNAs, thus promoting tumor progression. Biological functions and mechanisms of ATB in human cancers are discussed here, concluding that lncRNA-ATB may provide a new biomarker for use in diagnosis and prognosis of cancer.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Long Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers
    Jin, Shi-Jia
    Jin, Ming-Zhu
    Xia, Bai-Rong
    Jin, Wei-Lin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [42] ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers
    Li, Zheng
    Yu, Xin
    Shen, Jianxiong
    TUMOR BIOLOGY, 2016, 37 (05) : 5657 - 5661
  • [43] The role of long non-coding RNA BCAR4 in human cancers
    Yi, Qiong
    Liu, Zhongcheng
    Zhang, Kun
    Liu, Xuening
    Wang, Lifu
    Geng, Bin
    Xia, Yayi
    HUMAN CELL, 2021, 34 (05) : 1301 - 1309
  • [44] Long non-coding RNA HOTTIP, a novel potential prognostic marker in cancers
    Hu, Linhui
    Li, Manman
    Ding, Yangyang
    Pu, Lianfang
    Liu, Jun
    Xiong, Shudao
    MINERVA MEDICA, 2017, 108 (01) : 95 - 97
  • [45] MEG3: an Oncogenic Long Non-coding RNA in Different Cancers
    Al-Rugeebah, Arwa
    Alanazi, Mohammed
    Parine, Narasimha Reddy
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (03) : 859 - 874
  • [46] Long Non-coding RNA ANRIL and Polycomb in Human Cancers and Cardiovascular Disease
    Aguilo, Francesca
    Di Cecilia, Serena
    Walsh, Martin J.
    LONG NON-CODING RNAS IN HUMAN DISEASE, 2016, 394 : 29 - 39
  • [47] Targeting long non-coding RNA as a novel treatment option in human cancers
    Kondo, Yutaka
    CANCER SCIENCE, 2018, 109 : 346 - 346
  • [48] CASC19: An Oncogenic Long Non-coding RNA in Different Cancers
    Wu, Yinxin
    Mou, Jie
    Zhou, Gang
    Yuan, Chengfu
    CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (15) : 1157 - 1166
  • [49] The different prognostic value of long non-coding RNA BANCR in human cancers
    Hu, Linhui
    Li, Manman
    Pu, Lianfang
    Ding, Yangyang
    Liu, Jun
    Xiong, Shudao
    MINERVA MEDICA, 2017, 108 (01) : 97 - 101
  • [50] MEG8: An Indispensable Long Non-coding RNA in Multiple Cancers
    Du, Zhuoying
    Tan, Fangshun
    Chen, Jinlan
    Wang, Bei
    Liu, Yuling
    Zhao, Fangnan
    Wu, Yinxin
    Yuan, Chengfu
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (20) : 1688 - 1694